| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/25/2002 | US20020048785 Novel polypeptides within the tumor necrosis factor receptor superfamily and uses therefor |
| 04/25/2002 | US20020048748 Controlling human lymphocyte leukemia/lymphoma viruses immunodeficiency virus; obtain human, administer viricide and interleukin, monitor human for adjust in viral activity |
| 04/25/2002 | US20020048594 Topically applying onto the skin, hair and/or mucous membranes |
| 04/25/2002 | US20020048583 Combining ex vivo an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen |
| 04/25/2002 | US20020048565 Mammalian tolloid-like gene and protein |
| 04/25/2002 | US20020048271 Methods and composition for restoring conformational stability of a protein of the p53 family |
| 04/25/2002 | DE10051321A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are potent neurokinin antagonists, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | DE10051320A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are neurokinin antagonists having a long duration of action, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | DE10050334A1 Composition comprising stem cells and CD6-depleted stem cells, useful for inducing transplant tolerance and for treatment, especially of leukemia, administered separately |
| 04/25/2002 | CA2818654A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | CA2464121A1 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 04/25/2002 | CA2464092A1 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | CA2453140A1 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | CA2426604A1 Compounds with high monoamine transporter affinity |
| 04/25/2002 | CA2426592A1 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | CA2426381A1 Cell damage inhibitor |
| 04/25/2002 | CA2426337A1 Substituted imidazoles useful in the treatment of inflammatory diseases |
| 04/25/2002 | CA2426271A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | CA2426103A1 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents |
| 04/25/2002 | CA2425963A1 Human kinases |
| 04/25/2002 | CA2425900A1 Novel medicinal herbal composition for treating liver diseases and hiv |
| 04/25/2002 | CA2425804A1 Urotensin-ii agonists and antagonists |
| 04/25/2002 | CA2425763A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/25/2002 | CA2425742A1 Methods of selecting compounds for modulation of bladder function |
| 04/25/2002 | CA2425669A1 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 04/25/2002 | CA2425662A1 Osteopontin-coated surfaces and methods of use |
| 04/25/2002 | CA2425221A1 Protein c or activated protein c-like molecules |
| 04/25/2002 | CA2424689A1 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | CA2423933A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | CA2423843A1 Uses of monoclonal antibody 8h9 |
| 04/25/2002 | CA2423789A1 Bridged piperazine derivatives |
| 04/25/2002 | CA2421597A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | CA2419388A1 Substituted dipeptides as growth hormone secretagogues |
| 04/24/2002 | EP1199372A2 Polymorphisms in the human P2X7 gene |
| 04/24/2002 | EP1199361A2 Glycoprotein hormone receptor molecules. Their uses |
| 04/24/2002 | EP1199358A1 Gene encoding promoter domain of tumor suppressor gene p51 and use thereof |
| 04/24/2002 | EP1199306A1 Biarylurea derivatives |
| 04/24/2002 | EP1199076A2 Medicament containing tocotrienol as active component |
| 04/24/2002 | EP1199071A2 Use of an estrogen agonist/antagonist for improving vascular health |
| 04/24/2002 | EP1199070A2 Use of PDE V inhibitors for improved fecundity in mammals |
| 04/24/2002 | EP1199069A2 Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health |
| 04/24/2002 | EP1199068A2 NMDA NR2B antagonists for treating depression and neurodegenerative disorders |
| 04/24/2002 | EP1199067A2 Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists |
| 04/24/2002 | EP1198570A1 Monomeric protein of the tgf-beta family |
| 04/24/2002 | EP1198568A1 Compositions and methods for the treatment of immune related diseases |
| 04/24/2002 | EP1198563A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 04/24/2002 | EP1198556A2 Methods for producing and preparing cells for cell therapy |
| 04/24/2002 | EP1198255A1 Identification of compounds that modify transcriptional responses to hypoxia |
| 04/24/2002 | EP1198241A1 Novel proteins |
| 04/24/2002 | EP1198240A2 Tissue regenerating agent |
| 04/24/2002 | EP1198238A2 Gene encoding nade, p75ntr -associated cell death executor and uses thereof |
| 04/24/2002 | EP1198232A1 Urea substituted imidazoquinolines |
| 04/24/2002 | EP1198231A1 Bicyclic antagonists selective for the(alpha)v(beta)3 integrin |
| 04/24/2002 | EP1198230A1 Use of creatine or creatine compounds for skin preservation |
| 04/24/2002 | EP1180366A9 Neuronal death inhibitors |
| 04/24/2002 | EP1051180B1 Phospholipids having antimicrobial activity with the presence of antimicrobials |
| 04/24/2002 | EP1007063A4 Bone regeneration in osteoporosis using human bone marrow mesenchymal cells |
| 04/24/2002 | EP0863911B1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION |
| 04/24/2002 | EP0788388B1 Device for aerosolized delivery of peptide drugs |
| 04/24/2002 | EP0782568B1 Aromatic ethers derived from indols such as 5ht1-like ligands |
| 04/24/2002 | EP0714299B1 Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists |
| 04/24/2002 | CN1346403A Method and apparatus or maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| 04/24/2002 | CN1346370A Polypeptides involved in immune response |
| 04/24/2002 | CN1346368A Potassium channel interactors and uses therefor |
| 04/24/2002 | CN1346366A Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients |
| 04/24/2002 | CN1346365A Macrocylic peptides active against the hepatitis C virus |
| 04/24/2002 | CN1346358A Thienopyrimidine compounds and salts thereof and process for the preparation of the same |
| 04/24/2002 | CN1346356A 治疗性的核苷化合物 Therapeutic nucleoside compound |
| 04/24/2002 | CN1346355A Novel inhibitors of farnesyl-protein transferase |
| 04/24/2002 | CN1346353A Farnesy transferase inhibitors having a pyrrole structure and process for preparation thereof |
| 04/24/2002 | CN1346350A Compound which inhibiti leukocyte adhesion mediated by VLA-4 |
| 04/24/2002 | CN1346349A Pyrazoelcarboxylic acid derivatives, their preparation, pharmaceutical compositions containing |
| 04/24/2002 | CN1346348A Amide compounds and medicinal use thereof |
| 04/24/2002 | CN1346344A Substituted 2-aminobenzamide caspase ihibitors and the use thereof |
| 04/24/2002 | CN1346290A Delivery of macromolecules into cells |
| 04/24/2002 | CN1346283A External coated chewing gum products |
| 04/24/2002 | CN1346282A Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia |
| 04/24/2002 | CN1346275A Treatment of accidental extravasation of anthracyclines |
| 04/24/2002 | CN1346274A Formulation comprising testosteron undecanoate and castor oil |
| 04/24/2002 | CN1346272A Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 04/24/2002 | CN1346270A Compositions having improved stability |
| 04/24/2002 | CN1346269A Calcilytic compounds |
| 04/24/2002 | CN1345721A Process for preparing photoactivated (-) yellow skin amide |
| 04/24/2002 | CN1083455C photocurable glycosminoglycan derivatives, crosslinked glycosaminoglycans and method of production thereof |
| 04/24/2002 | CN1083453C Fused imidazole derivatives as emultidrug resistance modulators |
| 04/24/2002 | CN1083452C Pyrido (2,3-d) pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| 04/24/2002 | CN1083448C 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (D4) |
| 04/24/2002 | CN1083443C 吲哚衍生物 Indole derivatives |
| 04/24/2002 | CN1083431C Novel heterocyclic compounds |
| 04/24/2002 | CN1083429C Substituted alkyldiamine derivatives and their use as tachykinin antagonists |
| 04/24/2002 | CN1083419C Pentanoic acid derivatives, its preparation, medicinal materials having same and use thereof |
| 04/24/2002 | CN1083264C Pharmaceutical compositions comprising an opiate ant agonist and calcium salts, their use for the treatment of endorphin-mediated pathlogies |
| 04/24/2002 | CN1083244C Zilpaterol hydrochloride in specific crystallized formits prepn. process and intermediate products used |
| 04/24/2002 | CA2359606A1 Cysteine/glycine rich peptides |
| 04/23/2002 | US6376675 Pyridyl-1,2,5-thiadiazole derivatives |
| 04/23/2002 | US6376673 Central nervous system disorders |
| 04/23/2002 | US6376672 Restenosis; vision defects; cardiovascular disorders; kidney dieases |
| 04/23/2002 | US6376665 Antiarthritic agents, antiinflammatory agents |
| 04/23/2002 | US6376653 Tie2 antagonist antibodies |